Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
9th December 2014

Gynesonics Announces Another Peer-Reviewed Publication and Presentation of Significant International Clinical Experience With Vizablate Technology for Symptomatic Uterine Fibroids

5th December 2014

Abingworth appoints Kurt von Emster as a Partner In Menlo Park

24th November 2014

BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa’s Outstanding Stock

4th November 2014

Sientra® Announces Closing of Initial Public Offering

30th October 2014

Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals

15th October 2014

ABILITY Network to acquire MD-Online Inc

1st October 2014

Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

10th July 2014

Abingworth Promotes Ken Haas and Vin Miles to Partners

1st July 2014

Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement

1st July 2014

Paratek appoints Michael Bigham as Chairman and CEO and promotes Evan Loh to President and CMO

17th June 2014

Pixium Vision raises €34.5 million (US$ 46.7 million) in successful IPO on Euronext Paris, after full exercise of the extension clause

16th June 2014

Avillion elects Ulf Wiinberg, CEO of Lundbeck, as Chairman of its Board of Directors

5th June 2014

Senseonics Raises $20 Million; Brings in New VP of Sales and Marketing

31st May 2014

Lenvatinib Phase III Results Show Significant Improvement in Progression-Free Survival in Patients with Radioiodine-refractory Differentiated Thyroid Cancer

16th May 2014

Proteon Therapeutics Announces $45 Million of Series D Financing

6th May 2014

Avillion Announces Royalty Pharma Investment

22nd April 2014

Gynesonics Names Christopher M. Owens President, Chief Executive Officer

16th April 2014

Wilson Therapeutics Secures $40 Million Private Financing to Advance Late Stage Development Program for Wilson's Disease

26th March 2014

Pixium Vision appoints Khalid Ishaque as Chief Executive Officer

28th February 2014

Abingworth raises £225m ($375m) in its tenth

18th February 2014

Avillion appoints Dr Allison Jeynes-Ellis as Chief Executive Officer

3rd February 2014

Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

3rd February 2014

Ablynx Announces Worldwide Cancer Immunotherapy Discovery Collaboration and Licensing Agreement with Merck

9th January 2014

Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia